Stoke Therapeutics Appoints New CMO, Adds Director
Ticker: STOK · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-of-directors, personnel-change
TL;DR
Stoke Therapeutics beefs up leadership with a new CMO and board member.
AI Summary
Stoke Therapeutics, Inc. announced on June 18, 2024, the appointment of Dr. Barry L. Gelb as Chief Medical Officer and the election of Dr. Susan L. Robertson to its Board of Directors. Dr. Gelb will receive an annual base salary of $450,000 and stock options. Dr. Robertson will receive standard board compensation.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member signals potential strategic shifts and leadership changes within Stoke Therapeutics, impacting its future direction and operational focus.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events and do not inherently carry significant financial risk.
Key Numbers
- $450,000 — CMO Salary (Annual base salary for new Chief Medical Officer, Dr. Barry L. Gelb.)
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- Dr. Barry L. Gelb (person) — Appointed Chief Medical Officer
- $450,000 (dollar_amount) — Dr. Gelb's annual base salary
- Dr. Susan L. Robertson (person) — Elected to Board of Directors
- June 18, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the new Chief Medical Officer?
The filing states Dr. Barry L. Gelb has been appointed Chief Medical Officer, but does not detail his specific responsibilities beyond that title.
What is the compensation package for Dr. Susan L. Robertson as a board member?
The filing mentions Dr. Susan L. Robertson will receive standard board compensation, but does not specify the exact amount or details.
When did Dr. Gelb's appointment as CMO become effective?
The filing reports the event as of June 18, 2024, indicating the appointment is effective on or around this date.
What is the term of Dr. Robertson's directorship?
The filing announces her election to the Board of Directors but does not specify the length of her term.
Are there any stock options granted to Dr. Robertson?
The filing mentions stock options for Dr. Gelb but does not mention any for Dr. Robertson.
Filing Stats: 406 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-06-21 16:05:55
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo
Filing Documents
- d856457d8k.htm (8-K) — 22KB
- 0001193125-24-165651.txt ( ) — 141KB
- stok-20240618.xsd (EX-101.SCH) — 3KB
- stok-20240618_lab.xml (EX-101.LAB) — 18KB
- stok-20240618_pre.xml (EX-101.PRE) — 11KB
- d856457d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 45 Wiggins Ave Bedford , Massachusetts 01730 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: (781) 430-8200 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Certain Officers. On June 18, 2024, Stoke Therapeutics, Inc. (the "Company") and Huw Nash, Ph.D., the Company's Chief Operating Officer and Chief Business Officer, announced that they have mutually agreed that Dr. Nash would step down from his position as Chief Operating Officer, effective immediately. Dr. Nash will continue to serve and perform his duties as Chief Business Officer. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 21, 2024 STOKE THERAPEUTICS, INC. By: /s/ Thomas Leggett Thomas Leggett Chief Financial Officer